DRG Epidemiology's coverage of OPE comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of OPE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's OPE forecast will answer the following questions:

  • Of all people with OPE, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with OPE, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OPE over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following OPE patient populations:

  • Total prevalent cases
  • Total prevalent cases by diagnosis
  • Diagnosed prevalent cases by drug-treatment

Note: coverage may vary by country and region.

Table of contents

  • Mature Markets Data Osteopenia
    • Introduction
      • Key Findings
        • Key Findings
      • Overview
        • Total Prevalence of Osteopenia per 1,000 Among People Aged 40+ in 2017 and 2037
        • Relative Sizes of the Contributing Factors to the Trend in Osteopenia Over the Next 20 Years
        • Analysis of the Prevalent Cases of Osteopenia in 2017 by Diagnosed and Drug-Treated Status
    • Epidemiology Data
    • Methods
      • Total Prevalence
      • Diagnosed and Drug-Treated Prevalent Cases
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

With an increasing prevalence, due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches wil...

View Details

Osteoporosis | Unmet Need | Detailed, Expanded Analysis (US/EU)

Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength. A significant unmet need exists for treatment that is more effective than current therapies and we...

View Details

Osteoporosis | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of osteoporosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We repo...

View Details

Osteopenia | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of osteopenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report...

View Details